Investors with low to moderate tolerance must stand by diversified funds
Covid-19 has accelerated the growth of IT companies with rise in demand for digitisation
After the recent rally, direct investors need to be cautious about valuations
IT and pharma funds have returned 4.4% and 1.77% in the past month, respectively
Only savvy investors who are well informed about the sector's prospects should invest in technology funds